[go: up one dir, main page]

AU2003904328A0 - Diagnosis and treatment of neurodegenerative disorders - Google Patents

Diagnosis and treatment of neurodegenerative disorders

Info

Publication number
AU2003904328A0
AU2003904328A0 AU2003904328A AU2003904328A AU2003904328A0 AU 2003904328 A0 AU2003904328 A0 AU 2003904328A0 AU 2003904328 A AU2003904328 A AU 2003904328A AU 2003904328 A AU2003904328 A AU 2003904328A AU 2003904328 A0 AU2003904328 A0 AU 2003904328A0
Authority
AU
Australia
Prior art keywords
diagnosis
treatment
neurodegenerative disorders
neurodegenerative
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003904328A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Original Assignee
Garvan Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Institute of Medical Research filed Critical Garvan Institute of Medical Research
Priority to AU2003904328A priority Critical patent/AU2003904328A0/en
Publication of AU2003904328A0 publication Critical patent/AU2003904328A0/en
Priority to PCT/AU2004/001086 priority patent/WO2005017143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003904328A 2003-08-13 2003-08-13 Diagnosis and treatment of neurodegenerative disorders Abandoned AU2003904328A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003904328A AU2003904328A0 (en) 2003-08-13 2003-08-13 Diagnosis and treatment of neurodegenerative disorders
PCT/AU2004/001086 WO2005017143A1 (en) 2003-08-13 2004-08-13 Diagnosis and treatment of neurodegenerative disorders, involving the microtubule associated protein tau (mapt) gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003904328A AU2003904328A0 (en) 2003-08-13 2003-08-13 Diagnosis and treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AU2003904328A0 true AU2003904328A0 (en) 2003-08-28

Family

ID=32476605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003904328A Abandoned AU2003904328A0 (en) 2003-08-13 2003-08-13 Diagnosis and treatment of neurodegenerative disorders

Country Status (2)

Country Link
AU (1) AU2003904328A0 (en)
WO (1) WO2005017143A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101478977B (en) 2006-03-29 2013-03-27 维拉科治疗学控股有限公司 Treatment of neurodegenerative diseases
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
EP2578692B1 (en) * 2007-04-05 2016-06-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
WO2010112034A2 (en) * 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
US20110135613A1 (en) * 2009-12-03 2011-06-09 The J. David Gladstone Institutes Methods for treating apolipoprotein e4-associated disorders
AU2013203395A1 (en) 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
WO2014153236A1 (en) 2013-03-14 2014-09-25 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
TWI702046B (en) 2013-07-19 2020-08-21 美商Ionis製藥公司 Compositions for modulating tau expression
JOP20200228A1 (en) 2015-12-21 2017-06-16 Novartis Ag Compositions and methods for decreasing tau expression
JOP20190065A1 (en) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc Compounds and Methods for Reducing the Expression of TAU
CN109994154B (en) * 2017-12-30 2021-07-13 安诺优达基因科技(北京)有限公司 Screening device for candidate pathogenic genes of monogenic recessive genetic disease
JP7376040B2 (en) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 How to detect biomarker molecules in neurodegenerative diseases
CN111334570B (en) * 2020-04-03 2021-05-14 首都医科大学宣武医院 Primer probe composition for detecting DNA methylation level and application thereof

Also Published As

Publication number Publication date
WO2005017143A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL174185A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
AU2003900747A0 (en) Diagnosis and treatment of pancreatic cancer
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
PL378108A1 (en) Combination therapy for the treatment of immunoinflammatory disorders
GB2415378B (en) Treatment of neurodegenerative conditions
GB2422373B (en) Treatment of neurodegenerative conditions
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
GB0300783D0 (en) Treatment of neurodegenerative conditions
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
WO2005052191A8 (en) Compositions and methods for the diagnosis and treatment of tumor
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
AU2002952346A0 (en) Diagnosis and treatment of disorders
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases
AU2005901420A0 (en) Diagnosis and treatment of disorders
HK1091138A (en) Treatment of neurodegenerative conditions
AU2003237143A1 (en) Diagnosis and treatment of glaucoma